Granules India Limited

Granules India Limited is a leading vertically integrated pharmaceutical company based in Hyderabad, India. The company specializes in the entire pharmaceutical manufacturing value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). It is recognized as one of the world's largest manufacturers of high-volume off-patent drugs such as Paracetamol, Ibuprofen, Metformin, and Guaifenesin. In recent years, Granules has strategically shifted its focus toward complex generics, oncology, and specialized therapeutic areas like CNS and ADHD. The company is also expanding its presence in the Contract Development and Manufacturing Organization (CDMO) space, notably through the 2025 acquisition of Swiss-based Senn Chemicals AG to enter the high-growth peptide therapeutics market. With a global footprint spanning over 80 countries, Granules operates multiple state-of-the-art manufacturing facilities in India and the United States.